ANL 34.00 Decreased By ▼ -0.25 (-0.73%)
ASC 13.65 Increased By ▲ 0.30 (2.25%)
ASL 23.40 Increased By ▲ 0.80 (3.54%)
AVN 84.50 Increased By ▲ 0.80 (0.96%)
BOP 7.70 No Change ▼ 0.00 (0%)
BYCO 9.44 Increased By ▲ 0.07 (0.75%)
DGKC 110.70 Increased By ▲ 0.50 (0.45%)
EPCL 50.35 Decreased By ▼ -0.54 (-1.06%)
FCCL 22.79 Increased By ▲ 0.03 (0.13%)
FFBL 25.42 Decreased By ▼ -0.28 (-1.09%)
FFL 15.25 Decreased By ▼ -0.05 (-0.33%)
HASCOL 8.95 Decreased By ▼ -0.05 (-0.56%)
HUBC 78.10 Decreased By ▼ -0.90 (-1.14%)
HUMNL 6.15 Increased By ▲ 0.31 (5.31%)
JSCL 19.24 Increased By ▲ 0.54 (2.89%)
KAPCO 40.58 Increased By ▲ 1.19 (3.02%)
KEL 3.66 Decreased By ▼ -0.02 (-0.54%)
LOTCHEM 14.28 Decreased By ▼ -0.07 (-0.49%)
MLCF 42.80 Increased By ▲ 0.50 (1.18%)
PAEL 30.85 Decreased By ▼ -0.22 (-0.71%)
PIBTL 9.50 Increased By ▲ 0.05 (0.53%)
POWER 8.55 Increased By ▲ 0.11 (1.3%)
PPL 83.20 Decreased By ▼ -0.10 (-0.12%)
PRL 22.96 Increased By ▲ 0.19 (0.83%)
PTC 9.02 Decreased By ▼ -0.18 (-1.96%)
SILK 1.36 Decreased By ▼ -0.04 (-2.86%)
SNGP 38.80 Increased By ▲ 0.21 (0.54%)
TRG 163.20 Decreased By ▼ -0.02 (-0.01%)
UNITY 35.27 Increased By ▲ 0.34 (0.97%)
WTL 1.58 Increased By ▲ 0.13 (8.97%)
BR100 4,823 Increased By ▲ 23.58 (0.49%)
BR30 24,729 Increased By ▲ 35.54 (0.14%)
KSE100 45,066 Increased By ▲ 122.13 (0.27%)
KSE30 18,435 Increased By ▲ 51.53 (0.28%)

Coronavirus
VERY HIGH
Pakistan Deaths
18,537
10824hr
Pakistan Cases
845,833
419824hr
Sindh
288,680
Punjab
312,522
Balochistan
22,900
Islamabad
77,065
KPK
121,728
Business & Finance

Pfizer says analysis shows 3.8pc of participants experienced fatigue

  • It said the updated analysis was based on 8,000 trial participants.
  • Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial.
18 Nov 2020

NEW YORK: Pfizer Inc on Tuesday updated its analysis of the safety profile of its COVID-19 vaccine seen during its large, late-stage trial, saying that 3.8% of participants experienced fatigue after receiving a second dose of the shot.

It said the updated analysis was based on 8,000 trial participants. Pfizer said in a previous analysis that 3.7% of 6,000 volunteers had experienced fatigue.

Pfizer also added that there was a second adverse event with a frequency of at least 2% in the trial. The US drugmaker said 2% of participants experienced headaches after the second shot.